Ilamycins are dual inhibitors of ClpX and ClpC1 involved in proteostasis in Mycobacteria
Gao, Y.; Fang, C.; Zhou, B.; Hameed, H. M. A.; Sun, C.; Tian, X.; He, J.; Han, X.; Zhang, H.; Ju, J.; Chen, X.; Zhong, N.; Ma, J.; Xiong, X.; Zhang, T.
Show abstract
The mycobacterial caseinolytic protease (Clp) system has been recognized as a promising therapeutic target. In this study, we identified two novel ilamycin analogs, ilamycin E (ILE) and ilamycin F (ILF), both targeting the ClpC1 component of the ClpC1P1P2 proteasome. ILE potently disrupts ClpC1P1P2-mediated proteolysis, leading to delayed bactericidal activity, while ILF also binds ClpC1, albeit with lower affinity. Notably, we discovered a unique mutation in clpX and a novel insertion in clpC1, both conferring resistance to ILE and ILF in mycobacterium, validated by gene editing. Furthermore, ILE can also inhibit the proteolytic activity of ClpXP1P2 in a manner dependent on the substrates tag sequence and adaptor. This first demonstration of clpX- and clpC1-mediated ilamycin resistance underscores the potential of ilamycins to target multiple components of the Clp protease system, offering a novel dual-target strategy for combating mycobacterial infections.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- A Novel Approach to Combat Pseudomonas aeruginosa: Repurposing Pharmaceuticals for Inhibition of Phospholipase A 94%
- Characterization of TelE, an LXG effector exhibiting a conserved C-terminal glycine zipper motif required for toxicity 93%
- A Mycobacterium tuberculosis effector targets mitochondrion, controls energy metabolism and limits cytochrome c exit. 93%
Similar papers in this journal
- Drug degradation caused by mce3R mutations confers contezolid (MRX-I) resistance in Mycobacterium tuberculosis 95%
- Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis 94%
- Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays. 93%
Similar papers in this journal
- Antibiotic-adjuvants abolish resistance conferred by the Staphylococcus aureus erythromycin resistance methyltransferase in an Escherichia coli model 93%
- Investigating β-lactam drug targets in Mycobacterium tuberculosis using chemical probes 93%
- Evaluating the Link Between Efflux Pump Expression and Motility Phenotypes in Pseudomonas aeruginosa Treated with Virulence Inhibitors 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.